Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $44 to $47.
Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $47
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.